Short answer
Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on April 20, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 8.01 (Other Events). AACR 2026 presentation of Pb]VMT-α-NET, highlighting clinical or research updates for Perspective Therapeutics’ radiopharmaceutical pipeline.
Perspective Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- AACR 2026 presentation of Pb]VMT-α-NET, highlighting clinical or research updates for Perspective Therapeutics’ radiopharmaceutical pipeline
- Press release filed as Exhibit 99.2, where investors should review the underlying data and potential program implications
Item EX-99.1 · Exhibit EX-99.1
- Interim Phase 1/2a data support activity at 5.0 mCi: 10 of 23 Cohort 2 patients responded, a 43% investigator-assessed response rate
- Eight of 16 Cohort 2 patients with SSTR2-expressing tumors responded, representing a 50% response rate in this subgroup
- Safety profile remained favorable across 64 treated patients, with no dose-limiting toxicities, treatment-related discontinuations, or Grade 5 events
- 18 of 25 efficacy-evaluable patients remained progression-free and alive, while nine patients showed deepening responses
- Additional efficacy data from 23 Cohort 2 and eight Cohort 3 patients expected later in 2026, supporting potential regulatory engagement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Perspective Therapeutics, Inc. 8-K filings
Get the next CATX 8-K as it lands
Follow CATX for push alerts, or ask the research agent what this filing means.